US Bancorp DE decreased its position in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 18.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,378 shares of the biopharmaceutical company’s stock after selling 2,968 shares during the quarter. US Bancorp DE’s holdings in Esperion Therapeutics were worth $524,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Quantbot Technologies LP grew its holdings in shares of Esperion Therapeutics by 348.6% during the first quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 1,234 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of Esperion Therapeutics during the first quarter worth about $231,000. Xact Kapitalforvaltning AB purchased a new position in shares of Esperion Therapeutics during the first quarter worth about $250,000. Canada Pension Plan Investment Board purchased a new position in shares of Esperion Therapeutics during the second quarter worth about $333,000. Finally, Virginia Retirement Systems ET AL purchased a new position in shares of Esperion Therapeutics during the first quarter worth about $347,000.
NASDAQ ESPR opened at $47.57 on Friday. Esperion Therapeutics Inc has a 52-week low of $33.06 and a 52-week high of $82.68.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.70) by ($0.01). During the same period in the previous year, the firm earned ($1.92) earnings per share. research analysts anticipate that Esperion Therapeutics Inc will post -6.28 earnings per share for the current year.
In related news, major shareholder Target N. V. Biotech purchased 50,000 shares of the stock in a transaction that occurred on Friday, June 29th. The shares were purchased at an average price of $39.48 per share, with a total value of $1,974,000.00. Following the completion of the acquisition, the insider now directly owns 3,182,964 shares in the company, valued at approximately $125,663,418.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Roger S. Newton sold 17,700 shares of the firm’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $51.05, for a total value of $903,585.00. Following the transaction, the director now directly owns 615,726 shares in the company, valued at approximately $31,432,812.30. The disclosure for this sale can be found here. In the last three months, insiders have purchased 210,000 shares of company stock worth $8,683,700. Corporate insiders own 32.50% of the company’s stock.
Several equities analysts have issued reports on the company. BidaskClub lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 12th. ValuEngine lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 21st. Citigroup raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $57.00 to $75.00 in a report on Friday, August 17th. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. Finally, Cowen reaffirmed a “buy” rating and set a $95.00 price objective on shares of Esperion Therapeutics in a report on Monday, August 6th. Two analysts have rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $81.81.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Further Reading: How to Invest in Growth Stocks
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.